8-K: 23andMe Granted Second Extension to Regain Nasdaq Compliance, Stock to Move to Capital Market

23andMe has been granted a 180-day extension, until November 4, 2024, to regain compliance with Nasdaq's minimum bid price requirement, and its stock will move to the Nasdaq Capital Market on May 13, 2024.

Summary

• 23andMe received a notification from Nasdaq on May 9, 2024, granting them an additional 180 days, until November 4, 2024, to meet the minimum bid price requirement of $1.00 per share.
• This extension was granted because 23andMe met all other listing requirements except for the bid price and demonstrated an intention to rectify the deficiency.
• To receive this extension, 23andMe's Class A common stock will be transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective May 13, 2024.
• The company was initially notified of non-compliance on November 13, 2023, after its stock price remained below $1.00 for 30 consecutive business days.
• If the stock price closes at or above $1.00 for at least 10 consecutive business days before November 4, 2024, 23andMe will regain compliance.
• Failure to regain compliance by November 4, 2024, could result in delisting of the stock.
• 23andMe is considering options to regain compliance, including a potential reverse stock split, but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The document highlights a significant issue with the company's stock price and the risk of delisting, which is a negative signal for investors. While an extension was granted, the underlying problem remains unresolved.

Positives

• 23andMe has been granted a second extension to regain compliance with Nasdaq listing requirements, providing more time to address the low stock price.
• The company has demonstrated its intention to cure the deficiency, which was a factor in granting the extension.
• The stock will continue to trade on the Nasdaq Capital Market under the symbol ME, avoiding immediate delisting.

Negatives

• 23andMe's stock price has been below $1.00 for an extended period, leading to the initial non-compliance notice.
• There is no guarantee that the company will be able to regain compliance with the minimum bid price requirement.
• Failure to regain compliance by November 4, 2024, could result in the delisting of the stock from Nasdaq.

Risks

• The company faces the risk of delisting if it cannot increase its stock price to $1.00 or more for at least 10 consecutive business days before November 4, 2024.
• There is no assurance that the company's strategies, including a potential reverse stock split, will be successful in regaining compliance.
• The move to the Nasdaq Capital Market may be perceived negatively by investors.

Future Outlook

23andMe intends to monitor its stock price and consider options, including a reverse stock split, to regain compliance with Nasdaq listing requirements, but there is no guarantee of success.

Management Comments

• The company intends to continue to monitor the closing bid price of the Common Stock between now and November 4, 2024.
• The company will consider available options to regain compliance with the Minimum Bid Price Requirement, including initiating a reverse stock split.

Industry Context

This announcement reflects the challenges faced by companies with declining stock prices in maintaining their listing on major exchanges. It is not uncommon for companies to receive delisting notices and seek extensions to regain compliance.

Comparison to Industry Standards

• Many companies facing similar stock price declines have also received delisting notices from Nasdaq and other exchanges.
• The process of seeking an extension and potentially implementing a reverse stock split is a common strategy used by companies to regain compliance.
• Other companies in the biotech and genomics sector have faced similar challenges with maintaining stock prices above the minimum bid price.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment if the company fails to regain compliance.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers may have concerns about the long-term viability of the company.

Next Steps

• 23andMe will monitor its stock price between now and November 4, 2024.
• The company will consider options to regain compliance, including a reverse stock split.
• The company will need to achieve a stock price of $1.00 or more for at least 10 consecutive business days before November 4, 2024, to regain compliance.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, stock price, reverse stock split, 23andMe, ME, Nasdaq Capital Market